James Randolph Hunter Jr. - 12 Jun 2025 Form 3 Insider Report for Tonix Pharmaceuticals Holding Corp. (TNXP)

Role
Director
Signature
/s/ Jessica Morris, attorney-in-fact
Issuer symbol
TNXP
Transactions as of
12 Jun 2025
Net transactions value
$0
Form type
3
Filing time
13 Jun 2025, 16:40:33 UTC
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Hunter James Randolph Jr Director C/O TONIX PHARMACEUTICALS HOLDING CORP, 26 MAIN STREET, SUITE 101, CHATHAM /s/ Jessica Morris, attorney-in-fact 13 Jun 2025 0002071788

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding TNXP Stock Option 12 Jun 2025 Common Stock 2 $6240.00 Direct F1
holding TNXP Stock Option 12 Jun 2025 Common Stock 7,740 $34.54 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended, and is fully vested.
F2 The option vests on the date of the Company's 2026 annual meeting of stockholders, and was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended.